Montelukast Für Pädiatrische Patienten Von 6 Bis 14 Jahren Accord

Montelukast, the active ingredient in Montelukast Für Pädiatrische Patienten Von 6 Bis 14 Jahren Accord, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for the prophylaxis and chronic treatment of asthma, prevention of exercise‑induced bronchoconstriction, and symptomatic relief of allergic rhinitis in children aged 6 to 14 years.

GNH USA supplies Montelukast Für Pädiatrische Patienten Von 6 Bis 14 Jahren Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and allergic symptoms. - Asthma: provides prophylaxis and chronic control of bronchial asthma in children. - Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach. - Sore throat: mild irritation. - Rash: mild skin redness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or tongue. - Stevens‑Johnson syndrome: severe skin reaction. - Eosinophilic granulomatosis with polyangiitis: rare vasculitis. - Hepatic injury: abnormal liver enzymes. - Neuropsychiatric events: mood changes, depression, suicidal thoughts. - Anaphylaxis: severe allergic reaction.

Before initiating therapy, consider the following safety measures. - Monitor asthma control: assess symptom frequency and rescue inhaler use. - Assess hypersensitivity: avoid if known allergy to montelukast or excipients. - Caution in hepatic impairment: adjust use if liver disease is present. - Watch for neuropsychiatric symptoms: inform caregivers of mood or behavior changes. - Review concomitant medications: check for potential interactions. - Store at room temperature: keep in the original pack, protect from moisture.

Montelukast may interact with several drug classes; awareness helps maintain efficacy and safety.

Major Interactions (Avoid): - Rifampin: strong CYP3A4 inducer that can lower montelukast levels. - Carbamazepine: enzyme inducer reducing therapeutic effect. - Phenytoin: may decrease montelukast exposure. - Phenobarbital: induces metabolism, potentially reducing efficacy.

Moderate Interactions (Monitor Closely): - Fluoxetine or other SSRIs: may increase risk of neuropsychiatric events. - Sertraline: similar caution for mood changes. - Theophylline: concurrent use may require monitoring of respiratory status. - Beta‑agonists: combined bronchodilator effect should be evaluated.